MENU

Print This PageEmail this Page

eTNS for Depression

The Monarch external Trigeminal Nerve Stimulation (eTNS) System treats depression with signals delivered to the brain via the trigeminal nerve. Cranial nerve stimulation is used to treat depression, but until recently required invasive surgery for vagus nerve stimulation (VNS).

The Monarch eTNS system received CE Mark approval and is now available in the European Union and Canada. eTNS is indicated as adjunctive treatment for depression in patients ages 7 and older. If you are interested in trying eTNS for yourself or a loved-one, request more information and a NeuroSigma representative will contact you.

What is Depression?

Depression is a common and disabling medical condition. Many individuals continue to suffer from severe depression despite trying multiple antidepressant medications, often in combination. Currently, few effective options are available to people whose depression is resistant to drug therapies. Cranial nerve stimulation has been used to treat depression for more than a decade, but the Monarch eTNS System is the first safe and effective system that does not require surgery.

Electroconvulsive therapy (ECT) and VNS require hospitalization and/or surgery and may have serious side effects. The eTNS system offers an especially attractive option because it does not require surgery and has been shown to be successful at treating patients with medication resistant depression.

Change in Depression Symptoms After 8 Weeks of eTNS

Patients with major depression were enrolled to receive 8 weeks of eTNS. Subjects had an average decrease in symptom severity of 58% as measured by the Beck Depression Inventory BDI).

Treating Depression with eTNS

The eTNS system was developed and tested by doctors at the University of California, Los Angeles (UCLA). Clinical trials have shown it to be safe and effective for treating depression. The journal Epilepsy & Behavior published results in 2011 from the first trial of eTNS for the treatment of depression. Patients receiving eTNS for 8 weeks experienced an average decrease in symptom severity of 52%, according to the study. More recently, Neurology®, the journal of the American Academy of Neurology, published results of a trial involving 50 epilepsy patients. Although the trial focused on the reduction of epileptic seizures, the results also showed significant improvement in mood among those in the active treatment group independent of the anti-epileptic response to eTNS.

Treatment of depression with eTNS is easy and convenient. Patients use the system in the comfort of their own home. The device is about the size of a cell phone. A wire connects the device to a small patch that adheres to a patient's forehead, just above the eyebrows. Patients typically describe stimulation as a tingling sensation and most choose to deliver the therapy at night while they sleep.

Acquiring the eTNS System

To obtain a Monarch eTNS system, please contact us and a NeuroSigma representative will be in touch soon.

Back to Top